Multidisciplinary team, standards of care, optimal therapies, and novel agents in the care of cancer patients in Sub-Saharan Africa.

Eldoret, Kenya

27th July 2020- 26^th September2020

Lead Faculty: Dr. Chizi Kiti, MD

Head, Education and Training

International Cancer Institute (ICI)

P.O. Box 8088, Code 30100 Eldoret, Kenya

Email: ckiti@intercancer.com

Website: www.intercancer.com

This educational activity is provided by International Cancer Institute (ICI)

This activity is supported by educational grant from Roche through the ICI_Roche Shining Tower Project (STP)

Faculty

1. Chite Asirwa MD-Consultant Physician. Medical Oncologist & Hematologist, ICI
2. Kibet Kibor Keitany- Anatomic Pathologist
3. Irene Weru- Oncology Pharmacist
4. David Wata- Oncology Pharmacist
5. Collins Saina- Oncology Pharmacist (ICI)
6. Pamela Were- Oncology Nurse and Chief Outreach Coordinator (ICI)

This course will be accredited by KMPDC, KPPB and COC

Target Audience

The primary target audience for this course comprise the multidisciplinary clinical cancer care team members including, but not limited to oncology nurse practitioners and oncology nurses; Oncology pharmacists; Oncology Pharmaceutical Technologists; Oncology clinical officers; medical officers; General Practitioners; physician assistants; family physicians and other allied health care professionals.

LEARNING OBJECTIVES

At the end of this educational activity, participants should be able to:

1. Define cancer, characteristics of benign v/s malignant cells, cell cycle, cancer genetics and principles of carcinogenesis
2. Review the epidemiology of cancer, rationale for cancer screening and cancer prevention strategies.
3. Understand cancer diagnostic modalities, staging, goals of therapy and the role of multidisciplinary approach to the cancer patient.
4. Classify chemotherapy agents, give indications, contraindications, and specific adverse effects of each.
5. Familiarize with Immuno-oncology, Biologic and targeted cancer therapies
6. Know the various routes of anticancer drugs administration and the special considerations for use of each.
7. Learn the immediate complications of anticancer therapy, how to monitor them and their management.- including irritants, vesicants, hypersensitivity reactions etc
8. Review the systemic effects of anticancer therapy, their monitoring and management.
9. Learn the pathophysiology, grading, prevention and management of cancer-induced nausea and vomiting (CINV).
10. Understand the presentation and management of oncologic emergencies.
11. To learn about the role of pharmacovigilance in cancer care: counselling and education to patients and their families.
12. To discuss the legal and ethical issues related to cancer treatment
13. To demonstrate clinical acumen and practical skills in anticancer therapy administration processes.

Disclosure of Conflicts of Interest
International Cancer Institute (ICI) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ICI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty must report any financial relationships or contractual relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available.

The Program

Eight weeks of online learning- 2 webinars a week with further reading, assignments and discussion on the ICI elearning platform elearning.intercancer.com followed by 1 week of Practicum and hands- on skills training at the ICI Eldoret campus

LECTURES

Orientation to the course (Chizi) Monday, 27^th July 2020 4:00-4.30 pm EAT

1. Cancer definition, epidemiology, Screening and Prevention. (Kiti) Wednesday, 29^th July 2020 4.00- 5.30 PM EAT
2. Cancer Biology (Kibet) Monday, 3^rd August 2020 4.00- 5.30 pm EAT
3. Cancer Diagnosis, staging, goals of therapy and the multidisciplinary approach to the cancer patient (Kisilu) Wednesday, 5^th August 2020 4.00- 5.30 pm EAT
4. Types of Antineoplastic Therapies (Alkylating Agents, Antimetabolites, Antitumor Antibiotics, plant alkaloids etc) (Wata) Monday, 10^th August 2020 4.00- 5.30 pm EAT
5. Hormone Therapies (Wata) Wednesday, 12^th August 2020 4.00- 5.30 pm EAT
6. Immuno-oncology, Biologic and targeted cancer therapies (Chite) Monday, 17^th August 2020 4.00- 5.30 pm EAT
7. Safe handling of hazardous drugs, Occupational Exposure and hierarchic order of protection (Weru) Wednesday, 19^th August 2020 4.00- 5.30 pm EAT
8. Routes of anticancer medication administration (Kisilu) Monday, 24^th August 2020 4.00- 5.30 pm EAT
9. Immediate complications of anticancer therapy and management-vesicant, irritants. (Kisilu) Wednesday, 26^th August 2020 4.00- 5.30 pm EAT
10. Systemic side effects of chemotherapy- (Saina) Monday, 31^st August 2020 4.00- 5.30 pm EAT
11. Cancer Induced Nausea and Vomiting (CINV)-(Kiti) Wednesday, 2^nd September 2020 4.00 – 5.30 pm EAT
12. Oncologic emergencies I-(Chite) Monday, 7^th September 2020 4.00 – 5.30 pm EAT
13. Oncologic emergencies II- (Chite) Wednesday, 9^th September 2020 4.00 – 5.30 pm EAT
14. Pharmacovigilance:- Role of counselling , Patient and family education in Anticancer medication administration (Saina) Monday, 14^th September 2020 4.00 – 5.30 pm EAT
15. Legal and Ethical Issues Related to Cancer Treatment- (Pamela) Wednesday, 16^th September 2020 4.00 pm- 5.30 pm EAT

Practicum (5 days)- upon successful completion of the theory sessions, an invitation will be sent to participants for this part of the course

1. Chemotherapy processes:

• Pre- chemo administration- prescription, treatment protocols, review, counselling,
• During- monitoring of chemotherapy
• Post chemotherapy- discharge instructions, counselling

2. Routes of Administration
3. Equipment for sterile cytotoxic reconstitution, transport and storage, Cleaning and Disposal of cytotoxic waste
4. Cytotoxic spill managements
5. Documentation

CCC 100: ICI Chemotherapy & Anticancer Administration Competency Course

Participants should be willing to spend at least 4 hours per week on this online course over a period of 8 weeks. (Duration 32 hours) and 5-days (40 hours) of Practicals/skills training.

All those interested in registration to this course, please send your information to education@intercancer.com or info@intercancer.com

Acknowledgement

ICI acknowledges that the funding for this preceptorship training has been proudly supported by Roche through the ICI_Roche Shining Tower Project (STP)